Drug intelligence / Profile preview

PLS-1

Development stage: Preclinical
Lead developer: Primetime
Modality: Small Molecules

Overview

PLS-1 is a small molecule agonist of the Adenosine receptor A1 (A1R) being developed by Primetime Life Sciences for the treatment of Major Depressive Disorder (MDD). Adenosine signaling is known to play a critical role in the regulation of sleep and mood, and A1R agonists have shown potential in modulating these pathways to exert antidepressant effects. By targeting the A1 receptor, PLS-1 aims to provide a novel therapeutic approach distinct from traditional monoamine-based antidepressants. The drug is currently in the preclinical stage of development.

Targets

ADORA1 (Adenosine receptor A1 subtype)

Beyond the preview

Go deeper on PLS-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLS-1.

Explore the full profile